Login / Signup

An Investigation into the Quality of Medicines in Yangon, Myanmar.

Md Rafiqul IslamNaoko YoshidaKazuko KimuraChisana UwatokoMohammad Sofiqur RahmanShoma KumadaJamie EndoKana ItoTsuyoshi TanimotoTheingi ZinHirohito Tsuboi
Published in: Pharmacy (Basel, Switzerland) (2018)
Many poor-quality medicines are supplied to patients mainly in developing countries. No systematic survey on counterfeit medicines has been conducted in Myanmar since 1999. The purpose of this study was to investigate the current situation of substandard or counterfeit medicines in Myanmar. Samples of oral medicines, cefuroxime axetil (CXM), donepezil hydrochloride (DN) and omeprazole (OM), and injections, ceftriaxone sodium (CTRX), and gentamicin sulfate (GM), were collected from pharmacies, hospitals, and wholesalers in Yangon, Myanmar in 2014. Authenticity and quality were verified. There were 221 (94%) foreign medicines among 235 collected samples. Five samples of GM and 1 DN sample were not registered with the Food and Drug Administration, Myanmar. In quality analysis, 36 samples out of 177 (20.3%) did not pass quantity tests, 27 samples out of 176 (15.3%) did not pass content uniformity tests, and 23 out of 128 samples (18.0%) did not pass dissolution tests. Three of the unregistered GM samples failed in both identification and microbial assay tests. Counterfeit GM is being sold in Yangon. Also, the quality of OM is a matter of concern. Poor-quality medicines were frequently found among the products of a few manufacturers. Regular surveys to monitor counterfeit and substandard medicines in Myanmar are recommended.
Keyphrases
  • healthcare
  • end stage renal disease
  • chronic kidney disease
  • cross sectional
  • ejection fraction
  • patient reported outcomes
  • human health